Tech Company Financing Transactions

Sera Prognostics Funding Round

On 11/15/2011, Sera Prognostics landed $19.3 million in Series A funding from Catalyst Health Ventures, Domain Associates and InterWest Partners.

Transaction Overview

Company Name
Sera Prognostics
Announced On
11/15/2011
Transaction Type
Venture Equity
Amount
$19,300,000
Round
Series A
Investors

Catalyst Health Ventures (Lead Investor) (Joshua Phillips)

Domain Associates (Lead Investor) (Kim Kamdar)

InterWest Partners (Lead Investor) (Douglas Fisher)

Osage Partners

UpStart Ventures Management (Dennis Farrar)

Proceeds Purpose
Sera will use the proceeds of this financing to complete the company's multi-center Proteomic Assessment of Preterm Risk (PAPR) clinical trial of its preterm birth diagnostic and commercially launch the test with the goal of demonstrating clinical benefit and economic savings under real-world conditions.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2749 East Parleys Way 200
Salt Lake City, UT 84109
USA
Phone
(801) 990-0520
Website
www.seraprognostics.com
Email Address
[email protected]
Overview
Sera Prognostics, Inc., was founded in January 2008 to develop diagnostic tests for early prediction of preterm birth, preeclampsia and other pregnancy complications.
Profile
Sera Prognostics LinkedIn Company Profile
Social Media
Sera Prognostics Company Twitter Account
Company News
Sera Prognostics News
Facebook
Sera Prognostics on Facebook
YouTube
Sera Prognostics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Gregory Critchfield
  Gregory Critchfield LinkedIn Profile  Gregory Critchfield Twitter Account  Gregory Critchfield News  Gregory Critchfield on Facebook
Chief Financial Officer
Jay Moyes
  Jay Moyes LinkedIn Profile  Jay Moyes Twitter Account  Jay Moyes News  Jay Moyes on Facebook
Chief Information Officer
Robert Harrison
  Robert Harrison LinkedIn Profile  Robert Harrison Twitter Account  Robert Harrison News  Robert Harrison on Facebook
Chief Scientific Officer
Jay Boniface
  Jay Boniface LinkedIn Profile  Jay Boniface Twitter Account  Jay Boniface News  Jay Boniface on Facebook
Vice President
Thomas Garite
  Thomas Garite LinkedIn Profile  Thomas Garite Twitter Account  Thomas Garite News  Thomas Garite on Facebook
VP - Bus. Development
Nadia Altomare
  Nadia Altomare LinkedIn Profile  Nadia Altomare Twitter Account  Nadia Altomare News  Nadia Altomare on Facebook
VP - Bus. Development
Douglas Fisher
  Douglas Fisher LinkedIn Profile  Douglas Fisher Twitter Account  Douglas Fisher News  Douglas Fisher on Facebook
VP - General Counsel
Benjamin Jackson
  Benjamin Jackson LinkedIn Profile  Benjamin Jackson Twitter Account  Benjamin Jackson News  Benjamin Jackson on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/14/2011: SalesVu venture capital transaction
Next: 11/15/2011: simplifyMD venture capital transaction

 

Share this article

 

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.